

ZS Pharma (ZSPH, Outperform, \$51 TP)

“High-Class Spec Pharma Company with Attractive Proprietary Ion-Trap Technology”

July 14, 2014

RESEARCH TEAM

Vamil Divan, MD

(212) 538-5394

vamil.divan@credit-suisse.com

Ari Jahja

(212) 325-7067

ariyanto.jahja@credit-suisse.com

Ronak H. Shah, Pharm.D., CFA

(212) 325-9799

ronak.shah@credit-suisse.com

■ Initiating coverage of ZS Pharma with an Outperform rating and \$51 target price.

We view ZS Pharma as a high-class specialty pharma that is well positioned to deliver strong long-term growth by developing novel drugs from their proprietary “ion-trap” technology, most notably ZS-9 for treatment of hyperkalemia (high potassium). The company is led by a management team with strong industry experience and post IPO is well capitalized to execute on its wholly-owned asset. Several catalysts are also in place that should drive further investor interest.

■ **Investment positives include:** (1) Compelling potential of lead late-stage asset ZS-9 in hyperkalemia; (2) Robust long-term double-digit growth outlook; and (3) Attractive risk/reward profile for upcoming catalysts.

■ **Investment risks include:** (1) Pipeline setbacks, specifically with ZS-9; (2) slower-than-expected market growth for novel anti-hyperkalemia agents; and (3) slower-than-expected uptake of ZS-9 specifically following an expected 2016 launch.

■ **Catalysts:** (1) ZS-9 – ZS004 phase 3 data readout; current study ongoing to establish a maintenance dose (4Q '14); (2) ZS-9 – Expected US and EU submission (1H 2015); (3) Read-through from RLYP's patiomer potential launch (2H 2015); (4) Possible ex-US licensing.

■ **Valuation:** Our \$51 target price is based on DCF valuation. We use a 11.5% WACC and forecast discounted cash flows through 2033, with no terminal value thereafter.

DISCLOSURE APPENDIX CONTAINS IMPORTANT DISCLOSURES, ANALYST CERTIFICATIONS, INFORMATION ON TRADE ALERTS, ANALYST MODEL PORTFOLIOS AND THE STATUS OF NON-U.S ANALYSTS. FOR OTHER IMPORTANT DISCLOSURES, visit www.credit-suisse.com/researchdisclosures or call +1 (877) 291-2683 US Disclosure: Credit Suisse does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Table of Contents (Click on Titles to Navigate Through Note)



Portfolio Manager's Summary






“High-Class Spec Pharma Company with Attractive Proprietary Ion-Trap Technology”



High-Class Company Developing Drugs with Novel Ion Trap Technology

- **Led by senior management team with deep industry expertise**
- **Main late-stage asset ZS-9 poised for growth given impressive efficacy and safety profile**
 - Successfully completed phase 2 and initial phase 3 study for use in broad group of patients with hyperkalemia
 - Potent, consistent efficacy along with very reasonable safety profile
 - Second phase 3 study (ZS004) ongoing, with expected readout in 4Q 2014
 - Potential NDA submission to the FDA in early 2015 and US approval/launch in 2016
 - We assume total peak revenues of ~\$1Bn in 2030; loss of exclusivity in 2033
 - Expect independent commercialization in the US with specialty sales force, which should drive substantial operating leverage
 - Ex-US licensing providing opportunity for incremental revenues; 1H 2017 launch target in EU
- **Near-term catalysts should drive investor interest and generate value**
 - **4Q 2014:** ZS-9 – ZS004 phase 3 data readout; current study ongoing (n = 275) to establish a maintenance dose
 - **1H 2015:** ZS-9 – Expected US and EU submission
- **Key risks include clinical setbacks, poor commercial execution, and earlier-than-expected generic competition**
- **Relypsa (RLYP) provides direct comparable for ZSPH**
 - RLYP also developing a drug for hyperkalemia (called patiromer)
 - Could come to US market in 2H 2015 (NDA submission in 3Q 2014), roughly 6-9 months **before** ZS-9
 - RLYP went through an IPO in November 2013, now with a ~\$820 million market cap
 - **We believe ZS-9 has a stronger overall profile than patiromer based on better efficacy/safety profile, more convenient once-daily dosing and ability to be stored at room temperature**

CS View on Main Controversies Surrounding ZSPH Shares

| Controversy | Bull Case | Bear Case | CS View | |
|---|--|--|---|--|
| Total addressable market for novel hyperkalemia products | Market potential for the novel agents could be more meaningful than currently expected given the aging population, the increased incidence conditions that lead to hyperkalemia and the limitations current treatment options. | Hyperkalemia market size might not be as large as some thought and it will take longer to build than investors realize. Physician familiarity with current treatment options such as with Kayexlate will take a long time to overcome. |  | We believe there is more upside risk rather than downside risk on current market assumptions given the unmet medical need that exists in the growing hyperkalemia market and the limitations of current treatment options. |
| Competitive potential of ZS-9 in the hyperkalemia market | Strong efficacy, safety/tolerability and convenience advantages should allow for ZS-9 to becoming the market leader in the hyperkalemia market. Peak sales for ZS-9 could reach ~\$1.5 billion assuming higher probability of success, strong pricing, higher patient penetration, and/or longer treatment duration. | ZS-9 is likely to post positive data in the ZS004 study but RLYP's patiomer will have the first mover advantage in gaining traction in the emerging hyperkalemia market. Questions around chronic use of ZS-9 and long-term safety could also limit ZS-9 upside, keeping peak sales in the ~\$600 million range. |  | We again are more bullish on the competitive potential of ZS-9 given a broad clinical dataset including all comers with hyperkalemia and more than 1,500 patients being exposed to the product in the company's rigorous development program. Relypsa's first-mover advantage is less important in this market that will take some time to develop, in our view. We assume a 2016 launch and probability-adjusted 2030 sales of ~\$1 billion |
| Pipeline opportunities for ZSPH | While the company has not disclosed much in terms of pipeline opportunities, the ion-trap technology has a strong rationale for use in areas such as hyperammonemia, which provides reason for longer-term upside. | Lack of compelling near-term pipeline opportunities a weakness to the ZSPH story, limiting longer-term valuation. Estimates. |  | While we do see some potential for ZSPH's technology to have applications in other diseases, we currently do not assign any value to any pipeline opportunities beyond ZS-9. |
| 2018-2025 Sales CAGR | 21% | 14% |  | 18% |
| Valuation | \$86 | \$27 |  | \$51 |

DCF-Derived Target Price Suggests ZSPH Is Worth \$51/Share


DCF valuation: \$51/share

- Key assumptions driving DCF valuation
 - DCF best captures the evolution of ZSPH's long-term outlook
 - We project cash flows through 2033, with no terminal value thereafter
 - WACC: 11.5% (higher than U.S. major pharma and large specialty pharma)

Valuation Snapshot

| WACC | DCF/Share |
|--------------|-------------|
| 9.5% | \$63 |
| 10.5% | \$57 |
| 11.5% | \$51 |
| 12.5% | \$46 |
| 13.5% | \$42 |

ZS004 Data and ZS-9 Submission/Approval Key Upcoming Catalysts



Several Factors Pose Downside Risk to Our \$51 Target Price

■ Clinical development setbacks could materially impact ZSPH's path to profitability

- We see high likelihood that ongoing second phase 3 study (ZS004) will deliver positive results based on ZS-9 data to date
- Success of ZS-9 especially important in the ZSPH story given lack of other compounds in advanced clinical development

■ Poor commercial execution in an immature market and in the face of a direct competitor could limit uptake of ZS-9

- Branded hyperkalemia market will also need to be successfully developed (by both ZSPH and RLYP) given lack of novel branded products into this market for many years
- Direct competitor Relypsa (RLYP) likely to beat ZSPH to the market by 6-9 months and could take significant share

■ Continued questions around long-term safety of zirconium could limit use, especially in the more lucrative chronic setting

- ZSPH data highlights daily exposure to zirconium from the diet much greater than amount released from therapeutic doses of ZS-9

■ Earlier-than-expected generic competition could limit long-term potential of ZS-009 and growth trajectory of ZSPH as an entity

- Current patent estate should protect product through 2033
- We believe extensive manufacturing scale and knowhow needed to produce ZS-9 will also limit the entry of generic competitors

ZS Pharma (ZSPH, Outperform, \$51 TP)

“High-Class Specialty Pharma Company with Attractive Proprietary Ion-Trap Technology”



Investment Thesis

- **Compelling potential of lead asset ZS-9** in hyperkalemia indication
- **Robust long-term double-digit growth outlook**
- **Attractive risk/reward profile for upcoming catalysts**

Catalysts

- (1) ZS-9 – ZS004 phase 3 data readout; current study ongoing to establish a maintenance dose (4Q '14); (2) ZS-9 – Expected US and EU submission (1H 2015); (3) Read-through from RLYP's patiomer potential launch (2H 2015); (4) Possible ex-US licensing.


Risks

- 1) Pipeline setbacks, specifically with ZS-9; (2) slower-than-expected market growth for novel anti-hyperkalemia agents; and (3) slower-than-expected uptake of ZS-9 specifically following an expected 2016 launch

Valuation

- 100% DCF, with projected cash flows through 2033. We use 11.5% WACC and assume no terminal value beyond 2033

ZS Pharma Stock Price



CS PharmaFilter



Valuation

ZS Pharma (ZSPH)

| | | | |
|------------------------|---------|--------------------------|-------|
| Current Price (Jul 10) | \$28.21 | Market Cap (\$ mm) | \$562 |
| % of 52-Week High | 92% | Enterprise Value (\$ mm) | \$639 |
| Target Price | \$51 | Short Interest (Days) | 0.6 |
| Upside / Downside (%) | 81% | | |

Credit Suisse Estimates vs. Consensus

Fiscal Year Ending December 31 (\$ in thousands, except per share data)

| ADMS | FY 2014 | | FY 2015 | | FY 2016 | | FY 2017 | |
|--------------|----------|-------|----------|-------|----------|-----------|----------|-----------|
| | EPS | Sales | EPS | Sales | EPS | Sales | EPS | Sales |
| CS Estimates | (\$1.82) | \$0 | (\$2.82) | \$0 | (\$0.36) | \$117,874 | (\$0.04) | \$176,804 |

Product Story

ZS-9 Poised to Play an Important Role in Underappreciated Hyperkalemia Market



Table of Contents (Click on Titles to Navigate Through Note)



ZS-9 has Potential to be a Best-in-Class Treatment

■ Unique zirconium silicate compound

- Selectively binds to potassium (not calcium or magnesium)

■ 10x the binding capacity of current standard of care (Kayexalate)

- Kayexalate also has unpredictable efficacy, causes significant GI side effects and has FDA warning for risk of colonic necrosis

■ Consistent results in ZS-009 studies to date

- ZS002 (phase 2) met primary endpoint for lowering potassium within 48 hours
- ZS003 (phase 3) met primary endpoint for lowering potassium within 48 hours (induction phase) and maintaining normal potassium levels for two weeks (maintenance phase)
- **ZS004 (phase 3) ongoing**
 - **Results expected in 4Q 2014 – Key upcoming catalyst**
 - Goal is to establish maintenance dose to allow for both chronic and acute indication in product label
- Longer-term safety studies also being conducted (ZS004e, ZS005)
 - ~1300 subjects will be exposed to ZS-9 at the time of NDA submission, with 1500+ patients exposed by time of approval
- **Conversations with physicians also highlight the excitement that exists for a product with ZS-9's profile**

■ CS assumes ZS-9 filing in 1H 2015 with 2016 US launch and 2017 EU launch

- Assume 80% probability of regulatory success
- Probability-adjusted peak US sales of ~\$933 million and total company sales of ~\$1 Bn in 2030
- Non-probability adjusted peak global product sales potential of ~\$1.7 billion in 2030
 - CS assumes ex-US opportunity will be done through a partner with ZSPH receiving a ~15% royalty on sales


ZS-9 Poised to Play an Important Role in Underappreciated Hyperkalemia Market

- **Hyperkalemia (high potassium) is a life-threatening condition defined by elevated levels of potassium (K+) in the blood**
 - Generally affects patients with chronic kidney disease, heart failure, high blood pressure and/or diabetes
 - Also exacerbated by some of the best drugs that we have available to treat some of these conditions (RAAS inhibitors)
 - Hyperkalemia can lead to cardiac events (arrhythmias, heart failure) and death
 - Current treatment options (diet, medication avoidance, Kayexalate, diuretics) limited by efficacy, safety or tolerability issues
- **Hyperkalemia market underappreciated given lack of branded treatment options**
 - Four million patients with hyperkalemia in the US currently
 - Incidence of conditions that lead to hyperkalemia (diabetes, chronic kidney disease and heart failure) all on the rise

Large Potential Addressable Market with Clear Need to Provide Room for Both ZSPH's ZS-9 and RLYP's Patiromer


- **Branded hyperkalemia market will need to be successfully developed (by both ZSPH and RLYP) given lack of new products into this market for many years**
- **Total addressable market (TAM) for chronic population estimated to be 2.5-3.0 million patients**
 - We believe this estimate may prove to be conservative given ZS-9's broad clinical dataset that includes all comers of hyperkalemia (CKD, HF, diabetes, RAAS inhibitors, etc)
- **ZS-9 will likely also have access to the acute (hospital) population over time**
 - ZS-9 demonstrated better time of onset data (similar drop at 4 hours compared to RLYP's patiromer drop at 48 hours)
 - Incremental ~2 million patients but ZSPH has stated it will initially focus their commercial efforts on the outpatient, specialist setting
 - Acute market could represented longer-term upside

ZS-9 Provides Efficacy, Safety and Convenience Benefits Over Relypsa's Patiromer



ZS-9 Launch Expected in 2016 With US Peak Sales of ~\$933 Million Expected in 2030


ZS-9 US Revenues
(Sales in \$ Million)



We are Conservative on ZS-9 Compared to Consensus Estimates for Relypsa's Patisomer

U.S. Revenue Estimates – ZS-9 vs. Patisomer ⁽¹⁾

(Sales in \$ Millions)



¹ Since Patisomer is Relypsa's only product, total company sales is assumed to be Patisomer sales

ZS003 and ZS004 are the Pivotal Phase 3 Studies for ZS-9

| Trial | Trial Type | Patient Population | Duration | Objective | Summary |
|------------------------------|-----------------------------|---|------------------------|---|--|
| ZS002 (Completed) | Double-blind RCT Phase 2 | N=90 Hyperkalemia, CKD 5.0–6.0 mEq/L | 48 hours | Proof of concept for ZS-9 rapidly lowering K ⁺ levels | Met primary endpoint for the 3 g and 10 g doses |
| ZS003 (Completed) | Double-blind RCT Phase 3 | N=753 Hyperkalemia regardless of etiology 5.0–6.5 mEq/L | 14 days | Confirm rapid K ⁺ control and POC for maintenance dosing | Met primary endpoint for the 2.5g, 5g and 10g doses, and met secondary endpoint for 5g and 10g doses in maintenance phase |
| ZS004/e (Ongoing) | Double-blind RCT Phase 3 | N=230 Hyperkalemia regardless of etiology >5.0 mEq/L | 1 Month + Extension | Establish a maintenance dose | Ongoing; results expected in Q4 '14 |
| ZS005 (Ongoing) | Open-label safety study | N=500 Hyperkalemia regardless of etiology >5.0 mEq/L | Up to 12 months | Establish long-term safety and efficacy | Enrollment start announced on June 26, 2014 |

Approximately 1,500+ Patients Will Be Exposed to Drug by Time of FDA Approval

Catalysts


Several Catalysts Should Drive Investor Interest and Generate Value



Table of Contents (Click on Titles to Navigate Through Note)



ZS004 Data and ZS-9 Submission/Approval Key Upcoming Catalysts



Investment Risks

Several Factors Pose Downside Risk to Our \$51 Target Price




Table of Contents (Click on Titles to Navigate Through Note)



Several Factors Pose Downside Risk to Our \$51 Target Price

■ Clinical development setbacks could materially impact ZSPH's path to profitability

- We see high likelihood that ongoing second phase 3 study (ZS004) will deliver positive results based on ZS-9 data to date
- Success of ZS-9 especially important in the ZSPH story given lack of other compounds in advanced clinical development

■ Poor commercial execution in an immature market and in the face of a direct competitor could limit uptake of ZS-9

- Branded hyperkalemia market will also need to be successfully developed (by both ZSPH and RLYP) given lack of novel branded products into this market for many years
- Direct competitor Relypsa (RLYP) likely to beat ZSPH to the market by 6-9 months and could take significant share

■ Continued questions around long-term safety of zirconium could limit use, especially in the more lucrative chronic setting

- ZSPH data highlights daily exposure to zirconium from the diet much greater than amount released from therapeutic doses of ZS-9

■ Earlier-than-expected generic competition could limit long-term potential of ZS-009 and growth trajectory of ZSPH as an entity

- Current patent estate should protect product through 2032
- We believe extensive manufacturing scale and knowhow needed to produce ZS-9 will also limit the entry of generic competitors

Valuation

We Assign a \$51 12-Month Target Price to ZSPH Shares






Table of Contents (Click on Titles to Navigate Through Note)



ZS-9 Key Driver of Long-Term ZS Pharma Estimates

ZS Pharma Revenue Breakup

(Sales in \$ Millions)



Key Modeling Assumptions

- ZS-09 receives US FDA approval in 2016
 - Achieves peak US revenues of ~\$1 Bn in 2030 (80% probability of success)
 - Assumes 12.5% penetration of total addressable market and \$550/month net price
- ZS-09 expected to go off patent in 2033
- Ex US royalty of 15% from potential ex-US licensee
- We assume the company will reach positive EBITDA in 2017

DCF-Derived Target Price Suggests ZSPH Is Worth \$51/Share

DCF valuation: \$51/share


- Key assumptions driving DCF valuation
 - DCF best captures the evolution of ZSPH's long-term outlook
 - We project cash flows through 2033, with no terminal value thereafter
 - WACC: 11.5% (higher than U.S. major pharma and large specialty pharma)

Valuation Snapshot

| WACC | DCF/Share |
|--------------|-------------|
| 9.5% | \$63 |
| 10.5% | \$57 |
| 11.5% | \$51 |
| 12.5% | \$46 |
| 13.5% | \$42 |

Risk/Reward Skewed to the Upside on Our DCF Forecasts

DCF Value/Share




- Our DCF forecast assumes discounted cash flows through 2033 and assumes no terminal value thereafter
- **Upside case scenario:** Pricing: \$675/Rx, Treatment Duration: 5 months/patient/year, Peak Penetration: 13.5%, POS: 85%
- **Base case scenario:** Pricing: \$550/Rx, Treatment Duration: 4.5 months/patient/year, Peak Penetration: 12.5%, POS: 80%
- **Downside scenario:** Pricing: \$500/Rx, Treatment Duration: 4.0 months, Peak Penetration: 11.0%, POS: 70%

Note: For purposes of this scenario analysis, we have looked at more bullish or more bearish assumptions of success and are not highlighting the full upside (e.g. takeout) or full downside (e.g. phase 3 study failure).


RLYP is Trading at ~110% Above Its IPO Price and at a Significant Premium to ZSPH

Indexed Performance Since RLYP's IPO



- IPO price (date): \$11 (November 14, 2013)
- Current stock price: \$23.30
- Market Capitalization: \$820 million

Indexed Performance Since ZSPH's IPO



- IPO price (date): \$18 (June 17, 2014)
- Current stock price: \$28.21
- Market Capitalization: \$562 million

Strength of ZSPH IPO May Limit Some Upside in Coming Months, but DCF-Based Valuation Suggests Significant Longer-Term Upside


■ ZSPH IPO included 6.8 million shares at \$18, up from 5 million at \$15-\$17/share

- Stock closed at \$28.38 after first day of trading (up 58%)


■ Stocks with outsized near-term performance often lag relative to other IPOs

- Longer-term performance is tied to hitting milestones and meeting investor expectations

Pricing at high end predicts strong near term performance



Returns after initial pop show that most value often priced in



Note: Analysis includes all biotech IPOs from 2010-present. Transactions that priced above the offer price include ZSPH, KITE, VSAR, QURE, RARE, DRNA, OPHT, ONTX, AGIO, OMED and BLUE.

Company Background



Table of Contents (Click on Titles to Navigate Through Note)



ZS Pharma (ZSPH) Is a High-Class Company with Proprietary Zirconium Silicate Technology

- ZS Pharma is a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat **renal, cardiovascular, liver and metabolic diseases**
- Proprietary **zirconium silicate technology** allows them to create highly selective ion traps that can reduce toxic levels of specific electrolytes without disturbing the balance of other electrolytes
- Initial focus is on **development of ZS-9**, its product candidate in phase 3 for the treatment of hyperkalemia
 - Hyperkalemia is a life-threatening condition in which elevated levels of potassium in the blood (greater than 5.0 mEq/L) increase the risk of muscle dysfunction, including cardiac arrhythmias and sudden cardiac death
- ZS Pharma is planning to submit its New Drug Application (US) and Marketing Authorization Application (EU) for ZS-9 in the first half of 2015
 - If approved, the company intends to commercialize ZS-9 in the US with their own specialty sales force targeting nephrologists and cardiologists and plans to seek one or more partners for commercialization in ex-US markets
- ZS Pharma was incorporated in the State of Delaware on February 5, 2008
 - The company's operations are located in Coppel, Texas and Menlo Park, California

Senior Management Team with Strong Industry Experience

Robert Alexander, PhD
Chief Executive Officer

- Director, Alta Partners; Principal, MPM Capital
- Business Development, Genentech

AltaPartners

Genentech
A Member of the Roche Group

Alvaro Guillem, PhD
President & Co-Founder

- Adams Respiratory Therapeutics
- VP Quality at Genzyme/Bone Care International

genzyme
ADAMS
RESPIRATORY
THERAPEUTICS™

Jeffrey Keyser, JD, PhD
COO & Co-Founder

- Chief Compliance Officer, Encysive
- VP Reg. Affairs & Dev., Adams Respiratory Therapeutics

ENCYSIVE™
PHARMACEUTICALS
ADAMS
RESPIRATORY
THERAPEUTICS™

Henrik Rasmussen, MD, PhD
*Chief Medical Officer and
Scientific Officer*

- Corporate VP and Head of Clinical Dev., Medical & Regulatory Affairs, Novo Nordisk N. America
- CMO, Nabi Biopharmaceuticals and GenVec

novo nordisk®
NABI
BIOPHARMACEUTICALS

Cynthia Smith
Chief Commercial Officer

- VP Market Access & Commercial Dev., Affymax
- Merck & Co. and White House (OMB)

AFFYMAX®

MERCK

Todd Creech
Chief Financial Officer

- CFO and VP of Business Development, SARcode Bioscience
- CFO Sirion Therapeutics

SARcode
bioscience

SIRION
Therapeutics

Adam Tomasi, PhD
Senior VP Corporate Development

- Principal, Alta Partners
- Chemist, Cytokinetics

AltaPartners

CYTOKINETICS

Further Details on ZS Pharma's Strong Senior Management Team

| Name | Position(s) | Comments |
|-------------------------------------|---|--|
| Robert Alexander, PhD | <i>Chief Executive Officer</i> | Dr. Alexander has been CEO since December 2013; He served as a member of board of directors since October 2012 and Chairman of the Board between March 2013 and March 2014. In the past he served as director at Alta Partners, Executive chairman & interim CEO of SARcode Biosciences, Principal in MPM Capital's BioEquities fund where he sourced opportunities and led due diligence efforts for both public and private investments, and worked in the Business Development group at Genentech. Dr. Alexander completed his post-doctoral fellowship at Stanford University in the Pathology department, holds a Ph.D. in Immunology from the University of North Carolina and a B.A. in Zoology from Miami University of Ohio. |
| Alvaro Guillem, PhD | <i>Co-Founder and President</i> | Dr. Guillem is co-founder of ZS Pharma and has served as President and a member of the board of directors since 2008. From February 2008 to December 2013, he served as the CEO. Dr. Guillem is a veteran of the pharmaceutical industry with over thirty years of leadership experience in bringing new therapies to market at both well-established and start-up companies. In the past he has held various positions at Ash Access Technology, Genzyme/Bone Care and Adams Respiratory Therapeutics. Dr. Guillem holds a B.S. in Chemistry from Mary Washington University and a Ph.D. in Chemistry from Virginia Commonwealth University. |
| Jeffrey Keyser, JD, PhD | <i>Co-Founder and Chief Operating Officer</i> | Dr. Keyser is a co-founder of ZS Pharma and has served as the Secretary, Chief Operating Officer, and member of the board of directors since 2008. He has over thirty years of experience in the pharmaceutical industry in regulatory, medical, clinical and product development and has directed efforts to develop, prepare and secure approvals of numerous INDs and NDAs in the United States, Canada, Australia and Europe. In the past he held various positions at Encysive Pharmaceuticals, Adams Respiratory Therapeutics, Medeva Americas, Marion Merrell Dow, Marion Laboratories and Abbott Laboratories. Dr. Keyser received his B.S. in Pharmacy and J.D. from Creighton University, holds an MPA from the University of Missouri at Kansas City and a Ph.D. in Economics from the University of Texas at Dallas. |
| Henrik S. Rasmussen, MD, PhD | <i>Chief Medical Officer and Chief Scientific Officer</i> | Dr. Rasmussen has served as the Chief Medical Officer and Chief Scientific Officer since October 2012. He has led numerous global development programs and regulatory filings worldwide, including NDAs and has over 150 published peer-reviewed papers in therapeutic areas including nephrology, cardiology and diabetes. In the past he held various positions at Rasmussen Biotech and Pharma Consulting, Novo Nordisk, Nabi Biopharmaceuticals, Genvec, British Biotech and Pfizer Central research. Dr. Rasmussen received his M.D. and Ph.D. from the University of Copenhagen in Denmark and is trained in internal medicine and cardiology. |
| Cynthia Smith | <i>Chief Commercial Officer</i> | Ms. Smith has served as the Chief Commercial Officer since June 2013. In the past she held various positions at Affymax Inc, Merck and Co, Healthcare System and Medicare Strategy, and in the White House Office of Management and Budget under the Clinton Administration. Ms. Smith earned her B.A. from the University of North Carolina at Chapel Hill, her M.S. in Public Policy from the Eagleton Institute at Rutgers University and her MBA from the Wharton School at the University of Pennsylvania. |
| Todd A. Creech | <i>Chief Financial Officer</i> | Mr. Creech has served as the Chief Financial Officer since August 2013 and as the Treasurer since February 2014. In the past he held various positions at SARcode Biosciences, Sirion Therapeutics and NovaQuest (the investment group within Quintiles, Inc). He also brings an additional ten years of biotech- and high-tech-specific consulting experience from his time at SRI International and Anderson Consulting. Mr. Creech holds undergraduate degrees in Finance and Accounting from Miami University of Ohio and an MBA from Duke University. |
| Adam Tomasi, PhD | <i>Senior Vice President, Corporate Development</i> | Dr. Tomasi has served as the VP of Corporate Development since August of 2013. Prior to ZS Pharma, he was a Principal at Alta Partners, a Venture Capital firm located in San Francisco. Prior to joining Alta, he completed fellowships in venture capital at MPM Capital and as an equity analyst at Lehman Brothers. Originally trained as an organic chemist, he spent seven years in early stage drug discovery with Gilead Sciences and Cytokinetics. He holds a B.S. in Chemistry from UC Berkeley, an MBA from the MIT Sloan School of Management, and a Ph.D. in Chemistry from UC Irvine, where he was a Fellow of the American Chemical Society and UC Regents and was a post-doctoral student at The Scripps Research Institute. |

ZS Pharma's Board of Directors

| Name | Position | Independent |
|--------------------------|--|-------------|
| Robert Alexander | <i>Chief Executive Officer, Director</i> | N |
| Alvaro Guillem | <i>President, Director</i> | N |
| Jeffrey Keyser | <i>Chief Operating Officer and Secretary, Director</i> | N |
| Marc Ostro | <i>Director</i> | Y |
| Guy Nohra | <i>Chairman & Director</i> | Y |
| John Whiting | <i>Director</i> | Y |
| Srinivas Akkaraju | <i>Director</i> | Y |

ZS Pharma's Executive and Director Compensation

2013 Executive Compensation

| Name | Position | Salary | Bonus | Option Awards | All Other Compensation | Total |
|---------------------------|---|-----------|-----------|---------------|------------------------|-------------|
| Robert Alexander * | <i>Chief Executive Officer</i> | \$291,667 | \$87,740 | \$799,710 | \$26,397 | \$1,205,466 |
| Alvaro Guillem | <i>President</i> | \$325,000 | \$113,750 | \$278,160 | \$27,065 | \$743,959 |
| Todd Creech * | <i>Chief Financial Officer</i> | \$113,144 | \$31,940 | \$499,392 | \$10,717 | \$655,227 |
| Henrik Rasmussen | <i>Chief Scientific Officer and Chief Medical Officer</i> | \$300,000 | \$90,000 | \$173,850 | \$34,318 | \$598,158 |

Non-Employee Director Compensation, effective June 17, 2014

| Non-Employee Director | Annual Retainer | Stock Options |
|---|-----------------|---------------|
| All non-employee members of the Board | \$35,000 | 12,000 |
| Additional retainer for Non-Executive Chairmen of the Board | \$20,000 | - |
| Chairman, Audit Committee: | \$7,500 | - |
| Chairman, Compensation Committee | \$5,000 | - |
| Chairman, Nominating and Corporate Governance Committee | \$5,000 | - |

* - Robert Alexander's employment began in March 2013 and Todd Creech's employment began in August 2013

Financial Statements



Table of Contents (Click on Titles to Navigate Through Note)



ZS Pharma Income Statement (2013A-2023E)

| | | FY 2014 | | | | | | | | | | | | | |
|--|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| | FY 2013 | Mar-14 1QA | Jun-14 2QE | Sep-14 3QE | Dec-14 4QE | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 |
| Product sales (US) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 77,874 | 170,964 | 284,640 | 467,077 | 570,706 | 765,824 | 818,410 | 871,973 |
| Milestones and royalty revenue (ex US) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 40,000 | 5,841 | 12,822 | 21,348 | 35,031 | 42,803 | 57,437 | 61,381 |
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 117,874 | 176,804 | 297,462 | 488,425 | 605,737 | 808,627 | 875,847 | 933,354 |
| COGS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21,525 | 42,254 | 67,467 | 106,880 | 122,811 | 159,253 | 165,450 | 173,638 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 96,349 | 134,550 | 229,995 | 381,545 | 482,926 | 649,374 | 710,397 | 759,715 |
| Research and development expenses | 24,508 | 5,259 | 5,000 | 4,000 | 3,741 | 18,000 | 23,000 | 24,840 | 26,082 | 26,864 | 27,670 | 28,501 | 29,356 | 29,943 | 30,242 |
| Selling, general and administrative expenses | 7,686 | 4,017 | 4,000 | 4,000 | 2,483 | 14,500 | 40,000 | 79,500 | 108,625 | 124,919 | 138,660 | 152,526 | 167,778 | 171,134 | 172,845 |
| Operating income (loss) | (32,194) | (9,276) | (9,000) | (8,000) | (6,224) | (32,500) | (63,000) | (7,991) | (157) | 78,212 | 215,215 | 301,900 | 452,240 | 509,321 | 556,628 |
| Interest (income) | (31) | (6) | (12) | (62) | (61) | (141) | (243) | (309) | (290) | (278) | (417) | (692) | (1,058) | (1,608) | (2,248) |
| Interest expense | 9 | 3 | 0 | 75 | 225 | 303 | 1,200 | 1,200 | 1,200 | 1,200 | 600 | 0 | 0 | 0 | 0 |
| Expense to mark warrants to market | 1,424 | 1,297 | 0 | 0 | 0 | 1,297 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other expense | 1 | (3) | 0 | 0 | 0 | (3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit (Loss) before tax | (33,597) | (10,567) | (8,988) | (8,013) | (6,388) | (33,956) | (63,957) | (8,882) | (1,067) | 77,290 | 215,032 | 302,592 | 453,297 | 510,929 | 558,876 |
| Income tax expense (benefit) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,546 | 53,973 | 113,472 | 169,987 | 191,598 | 209,579 |
| Net profit (loss) | (33,597) | (10,567) | (8,988) | (8,013) | (6,388) | (33,956) | (63,957) | (8,882) | (1,067) | 75,745 | 161,059 | 189,120 | 283,311 | 319,330 | 349,298 |
| Preferred stock accretion | (689) | (181) | | | | (181) | 0 | | | | | | | | |
| Pro forma net profit (loss) | (32,862) | (9,451) | (8,988) | (8,013) | (6,388) | (34,137) | (63,957) | (8,882) | (1,067) | 75,745 | 161,059 | 189,120 | 283,311 | 319,330 | 349,298 |
| Weighted avg. shares used to calculate diluted EPS | 10,366 | 12,575 | 20,819 | 20,853 | 20,888 | 18,784 | 22,698 | 24,646 | 24,819 | 28,332 | 28,505 | 28,677 | 28,849 | 29,022 | 29,194 |
| EPS - Diluted | (\$3.17) | (\$0.75) | (\$0.43) | (\$0.38) | (\$0.31) | (\$1.82) | (\$2.82) | (\$0.36) | (\$0.04) | \$2.67 | \$5.65 | \$6.59 | \$9.82 | \$11.00 | \$11.96 |
| Depreciation and amortization | 705 | 241 | 257 | 369 | 482 | 1,348 | 2,930 | 3,609 | 4,294 | 5,265 | 6,415 | 7,236 | 7,578 | 6,863 | 6,530 |
| EBITDA | (31,489) | (9,035) | (8,743) | (7,631) | (5,742) | (31,152) | (60,070) | (4,381) | 4,137 | 83,477 | 221,630 | 309,136 | 459,818 | 516,183 | 563,158 |
| Margin Analysis | | | | | | | | | | | | | | | |
| Gross margin (overall) | | | | | | | | 81.7% | 76.1% | 77.3% | 78.1% | 79.7% | 80.3% | 81.1% | 81.4% |
| R&D margin (overall) | | | | | | | | 21.1% | 14.8% | 9.0% | 5.7% | 4.7% | 3.6% | 3.4% | 3.2% |
| SG&A margin (overall) | | | | | | | | 67.4% | 61.4% | 42.0% | 28.4% | 25.2% | 20.7% | 19.5% | 18.5% |
| EBITDA margin | | | | | | | | -3.7% | 2.3% | 28.1% | 45.4% | 51.0% | 56.9% | 58.9% | 60.3% |
| Operating margin | | | | | | | | -6.8% | -0.1% | 26.3% | 44.1% | 49.8% | 55.9% | 58.2% | 59.6% |
| Statutory tax rate | 37.5% | 37.5% | 37.5% | 37.5% | 37.5% | 37.5% | 37.5% | 37.5% | 37.5% | 37.5% | 37.5% | 37.5% | 37.5% | 37.5% | 37.5% |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.0% | 25.1% | 37.5% | 37.5% | 37.5% | 37.5% |
| Net income margin | | | | | | | | -7.5% | -0.6% | 25.5% | 33.0% | 31.2% | 35.0% | 36.5% | 37.4% |
| Year/Year Changes | | | | | | | | | | | | | | | |
| Product revenue | | | | | | | | NM | 119.5% | 66.5% | 64.1% | 22.2% | 34.2% | 6.9% | 6.5% |
| Total revenue | | | | | | | | NM | 50.0% | 68.2% | 64.2% | 24.0% | 33.5% | 8.3% | 6.6% |
| Gross profit | | | | | | | | NM | 39.6% | 70.9% | 65.9% | 26.6% | 34.5% | 9.4% | 6.9% |
| R&D | | | | | | | | 8.0% | 5.0% | 3.0% | 3.0% | 3.0% | 3.0% | 2.0% | 1.0% |
| SG&A | | | | | | | | 98.8% | 36.6% | 15.0% | 10.0% | 10.0% | 10.0% | 2.0% | 1.0% |
| EBITDA | | | | | | | | NM | NM | 1917.8% | 165.5% | 39.5% | 48.7% | 12.3% | 9.1% |
| Operating margin | | | | | | | | NM | NM | NM | 175.2% | 40.3% | 49.8% | 12.6% | 9.3% |
| Net income | | | | | | | | NM | NM | NM | 112.6% | 17.4% | 49.8% | 12.7% | 9.4% |

ZS Pharma Balance Sheet (2013A-2023E)

| | | FY 2014 | | | | | | | | | | | | | |
|---|---------------|---------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|------------------|------------------|
| | FY 2013 | Mar-14 1QA | Jun-14 2QE | Sep-14 3QE | Dec-14 4QE | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 |
| ASSETS | | | | | | | | | | | | | | | |
| Current assets: | | | | | | | | | | | | | | | |
| Cash and cash equivalents | 9,170 | 23,833 | 123,955 | 122,095 | 120,751 | 120,751 | 154,555 | 144,914 | 139,206 | 208,363 | 346,137 | 528,786 | 803,922 | 1,124,107 | 1,474,240 |
| Restricted cash | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Prepaid expenses | 71 | 60 | 100 | 100 | 100 | 100 | 150 | 1,259 | 2,654 | 3,289 | 4,098 | 4,558 | 5,346 | 5,498 | 5,651 |
| Other current assets | 6 | 732 | 1,000 | 1,000 | 1,000 | 1,000 | 1,200 | 2,835 | 6,165 | 12,260 | 20,123 | 26,285 | 35,209 | 37,802 | 40,279 |
| Total current assets | 9,397 | 24,775 | 125,205 | 123,345 | 122,001 | 122,001 | 156,055 | 149,008 | 148,025 | 223,912 | 370,358 | 559,629 | 844,476 | 1,167,407 | 1,520,170 |
| Property and equipment, net | 4,625 | 5,843 | 8,586 | 11,217 | 13,675 | 13,675 | 20,745 | 27,135 | 32,842 | 37,577 | 41,162 | 43,926 | 46,347 | 46,985 | 47,955 |
| Other assets | 24 | 24 | 100 | 100 | 100 | 100 | 200 | 1,179 | 3,536 | 5,949 | 9,769 | 12,115 | 16,173 | 17,517 | 18,667 |
| TOTAL ASSETS | 14,046 | 30,642 | 133,892 | 134,663 | 135,776 | 135,776 | 177,000 | 177,322 | 184,403 | 267,437 | 421,288 | 615,669 | 906,996 | 1,231,909 | 1,586,792 |
| LIABILITIES & STOCKHOLDERS' EQUITY | | | | | | | | | | | | | | | |
| Current liabilities: | | | | | | | | | | | | | | | |
| Accounts payable | 1,489 | 2,455 | 1,973 | 2,192 | 1,705 | 1,705 | 2,208 | 5,173 | 6,788 | 7,809 | 8,982 | 8,324 | 9,764 | 10,042 | 10,321 |
| Accrued liabilities | 3,114 | 2,288 | 2,160 | 2,240 | 1,743 | 1,743 | 2,480 | 3,776 | 5,309 | 6,578 | 8,196 | 9,115 | 10,692 | 10,996 | 11,302 |
| Current portion of long term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15,000 | 0 | 0 | 0 | 0 | 0 |
| Current portion of capital lease obligation | 73 | 37 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total current liabilities | 4,676 | 4,780 | 4,133 | 4,432 | 3,448 | 3,448 | 4,688 | 8,948 | 12,096 | 29,386 | 17,179 | 17,439 | 20,456 | 21,038 | 21,623 |
| Deferred rent | 67 | 69 | 69 | 69 | 69 | 69 | 69 | 69 | 69 | 69 | 69 | 69 | 69 | 69 | 69 |
| Lease incentive | 184 | 161 | 146 | 131 | 116 | 116 | 56 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term debt | 0 | 0 | 0 | 7,500 | 15,000 | 15,000 | 15,000 | 15,000 | 15,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital lease obligation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Series B redeemable preferred stock warrant liability | 2,667 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total liabilities | 7,594 | 5,010 | 4,348 | 12,132 | 18,633 | 18,633 | 19,813 | 24,017 | 27,165 | 29,455 | 17,248 | 17,508 | 20,525 | 21,107 | 21,692 |
| Commitments and contingencies: | | | | | | | | | | | | | | | |
| Convertible, redeemable preferred stock, Series B | 8,387 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Convertible, redeemable preferred stock, Series C | 43,247 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stockholders' equity | | | | | | | | | | | | | | | |
| Convertible preferred stock, Series A | 1,196 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Common stock, \$0.001 par value | 2 | 14 | 18 | 18 | 18 | 18 | 22 | 22 | 22 | 22 | 22 | 22 | 23 | 23 | 23 |
| Additional paid-in capital | 3,854 | 86,419 | 199,315 | 200,315 | 201,315 | 201,315 | 305,311 | 310,311 | 315,311 | 320,311 | 325,311 | 330,311 | 335,310 | 340,310 | 345,310 |
| Accumulated deficit | (50,234) | (60,801) | (69,789) | (77,802) | (84,190) | (84,190) | (148,147) | (157,028) | (158,096) | (82,351) | 78,708 | 267,828 | 551,139 | 870,469 | 1,219,767 |
| Total stockholders' equity | (45,182) | 25,632 | 129,544 | 122,531 | 117,143 | 117,143 | 157,186 | 153,305 | 157,237 | 237,982 | 404,041 | 598,161 | 886,472 | 1,210,802 | 1,565,100 |
| TOTAL LIABILITIES & STOCKHOLDERS' EQUITY | 14,046 | 30,642 | 133,892 | 134,663 | 135,776 | 135,776 | 177,000 | 177,322 | 184,403 | 267,437 | 421,288 | 615,669 | 906,996 | 1,231,909 | 1,586,792 |

ZS Pharma Statement of Cash Flows (2013A-2023E)

| | | FY 2014 | | | | | | | | | | | | | |
|---|-----------------|----------------|----------------|----------------|----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|------------------|------------------|
| | FY 2013 | Mar-14 1QA | Jun-14 2QE | Sep-14 3QE | Dec-14 4QE | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 |
| Operating activities: | | | | | | | | | | | | | | | |
| Net loss | (33,597) | (10,567) | (8,988) | (8,013) | (6,388) | (33,956) | (63,957) | (8,882) | (1,067) | 75,745 | 161,059 | 189,120 | 283,311 | 319,330 | 349,298 |
| Depreciation and amortization | 705 | 241 | 257 | 369 | 482 | 1,348 | 2,930 | 3,609 | 4,294 | 5,265 | 6,415 | 7,236 | 7,578 | 6,863 | 6,530 |
| Amortization of lease incentive | (18) | (23) | (15) | (15) | (15) | (68) | (60) | (56) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share-based expenses | 2,142 | 871 | 900 | 1,000 | 1,000 | 3,771 | 4,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 |
| Warrant expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Series B warrant mark-to-market expense | 1,424 | 1,297 | 0 | 0 | 0 | 1,297 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Loss on disposal of assets and other noncash income | (2) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | | | | | | | | | | | | | | | |
| Prepaid expenses and other assets | (84) | (753) | (384) | 0 | 0 | (1,137) | (350) | (3,722) | (7,083) | (9,143) | (12,491) | (8,968) | (13,770) | (4,090) | (3,780) |
| Accounts payable | 505 | 570 | (482) | 219 | (487) | (180) | 503 | 2,964 | 1,615 | 1,021 | 1,173 | (658) | 1,440 | 278 | 279 |
| Accrued expenses | 2,329 | (630) | (128) | 80 | (497) | (1,175) | 737 | 1,296 | 1,533 | 1,269 | 1,619 | 919 | 1,577 | 304 | 306 |
| Deferred rent | 67 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net cash from (used in) operating activities | (26,529) | (8,992) | (8,841) | (6,360) | (5,905) | (30,098) | (56,196) | 210 | 4,291 | 79,157 | 162,775 | 192,649 | 285,136 | 327,685 | 357,633 |
| Investing activities: | | | | | | | | | | | | | | | |
| Purchases of property and equipment | (3,771) | (1,061) | (3,000) | (3,000) | (2,939) | (10,000) | (10,000) | (10,000) | (10,000) | (10,000) | (10,000) | (10,000) | (10,000) | (7,500) | (7,500) |
| Net cash from (used in) investing activities | (3,771) | (1,061) | (3,000) | (3,000) | (2,939) | (10,000) | (10,000) | (10,000) | (10,000) | (10,000) | (10,000) | (10,000) | (10,000) | (7,500) | (7,500) |
| Financing activities: | | | | | | | | | | | | | | | |
| Proceeds from issuance of note payable, net | 0 | 0 | 0 | 7,500 | 7,500 | 15,000 | 0 | 0 | 0 | 0 | (15,000) | 0 | 0 | 0 | 0 |
| Proceeds from exercise of stock options | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Proceeds from exercise of warrants | 265 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Proceeds from issuance of restricted stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Proceeds from issuance of Series A preferred stock, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Proceeds from issuance of Series B preferred stock, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Proceeds from issuance of Series C preferred stock, net | 15,100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Proceeds from issuance of Series D preferred stock, net | 0 | 24,753 | 0 | 0 | 0 | 24,753 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Proceeds from issuance of common stock, net | 0 | 0 | 112,000 | 0 | 0 | 112,000 | 100,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Principal payments on capital lease | (146) | (37) | (37) | 0 | 0 | (74) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Restricted cash | (150) | 0 | 0 | 0 | 0 | 0 | 0 | 150 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net cash from (used in) by financing activities | 15,069 | 24,716 | 111,963 | 7,500 | 7,500 | 151,679 | 100,000 | 150 | 0 | 0 | (15,000) | 0 | 0 | 0 | 0 |
| Net (decrease) increase in cash and cash equivalents | (15,231) | 14,663 | 100,122 | (1,860) | (1,344) | 111,581 | 33,804 | (9,640) | (5,709) | 69,157 | 137,775 | 182,649 | 275,136 | 320,185 | 350,133 |
| Cash and cash equivalents at beginning of period | 24,401 | 9,170 | 23,833 | 123,955 | 122,095 | 9,170 | 120,751 | 154,555 | 144,914 | 139,206 | 208,363 | 346,137 | 528,786 | 803,922 | 1,124,107 |
| Cash and cash equivalents at end of period | 9,170 | 23,833 | 123,955 | 122,095 | 120,751 | 120,751 | 154,555 | 144,914 | 139,206 | 208,363 | 346,137 | 528,786 | 803,922 | 1,124,107 | 1,474,240 |

Disclosure Appendix

Important Global Disclosures

I, Vamil Divan, MD, certify that (1) the views expressed in this report accurately reflect my personal views about all of the subject companies and securities and (2) no part of my compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.

3-Year Price and Rating History for ZS Pharma, Inc. (ZSPH.OQ)

| ZSPH.OQ | Closing Price | Target Price | |
|-----------|---------------|--------------|--------|
| Date | (US\$) | (US\$) | Rating |
| 18-Jun-14 | 28.38 | | R |

* Asterisk signifies initiation or assumption of coverage.



The analyst(s) responsible for preparing this research report received Compensation that is based upon various factors including Credit Suisse's total revenues, a portion of which are generated by Credit Suisse's investment banking activities

As of December 10, 2012 Analysts' stock rating are defined as follows:

Outperform (O) : The stock's total return is expected to outperform the relevant benchmark* over the next 12 months.

Neutral (N) : The stock's total return is expected to be in line with the relevant benchmark* over the next 12 months.

Underperform (U) : The stock's total return is expected to underperform the relevant benchmark* over the next 12 months.

**Relevant benchmark by region: As of 10th December 2012, Japanese ratings are based on a stock's total return relative to the analyst's coverage universe which consists of all companies covered by the analyst within the relevant sector, with Outperforms representing the most attractive, Neutrals the less attractive, and Underperforms the least attractive investment opportunities. As of 2nd October 2012, U.S. and Canadian as well as European ratings are based on a stock's total return relative to the analyst's coverage universe which consists of all companies covered by the analyst within the relevant sector, with Outperforms representing the most attractive, Neutrals the less attractive, and Underperforms the least attractive investment opportunities. For Latin American and non-Japan Asia stocks, ratings are based on a stock's total return relative to the average total return of the relevant country or regional benchmark; prior to 2nd October 2012 U.S. and Canadian ratings were based on (1) a stock's absolute total return potential to its current share price and (2) the relative attractiveness of a stock's total return potential within an analyst's coverage universe. For Australian and New Zealand stocks, 12-month rolling yield is incorporated in the absolute total return calculation and a 15% and a 7.5% threshold replace the 10-15% level in the Outperform and Underperform stock rating definitions, respectively. The 15% and 7.5% thresholds replace the +10-15% and -10-15% levels in the Neutral stock rating definition, respectively. Prior to 10th December 2012, Japanese ratings were based on a stock's total return relative to the average total return of the relevant country or regional benchmark.*

Restricted (R) : In certain circumstances, Credit Suisse policy and/or applicable law and regulations preclude certain types of communications, including an investment recommendation, during the course of Credit Suisse's engagement in an investment banking transaction and in certain other circumstances.

Volatility Indicator [V] : A stock is defined as volatile if the stock price has moved up or down by 20% or more in a month in at least 8 of the past 24 months or the analyst expects significant volatility going forward.

Analysts' sector weightings are distinct from analysts' stock ratings and are based on the analyst's expectations for the fundamentals and/or valuation of the sector* relative to the group's historic fundamentals and/or valuation:

Overweight : The analyst's expectation for the sector's fundamentals and/or valuation is favorable over the next 12 months.

Market Weight : The analyst's expectation for the sector's fundamentals and/or valuation is neutral over the next 12 months.

Underweight : The analyst's expectation for the sector's fundamentals and/or valuation is cautious over the next 12 months.

**An analyst's coverage sector consists of all companies covered by the analyst within the relevant sector. An analyst may cover multiple sectors.*

Credit Suisse's distribution of stock ratings (and banking clients) is:

Global Ratings Distribution

| Rating | Versus universe (%) | Of which banking clients (%) |
|--------------------|---------------------|------------------------------|
| Outperform/Buy* | 44% | (54% banking clients) |
| Neutral/Hold* | 40% | (49% banking clients) |
| Underperform/Sell* | 13% | (48% banking clients) |
| Restricted | 3% | |

**For purposes of the NYSE and NASD ratings distribution disclosure requirements, our stock ratings of Outperform, Neutral, and Underperform most closely correspond to Buy, Hold, and Sell, respectively; however, the meanings are not the same, as our stock ratings are determined on a relative basis. (Please refer to definitions above.) An investor's decision to buy or sell a security should be based on investment objectives, current holdings, and other individual factors.*

Credit Suisse's policy is to update research reports as it deems appropriate, based on developments with the subject company, the sector or the market that may have a material impact on the research views or opinions stated herein.

Credit Suisse's policy is only to publish investment research that is impartial, independent, clear, fair and not misleading. For more detail please refer to Credit Suisse's Policies for Managing Conflicts of Interest in connection with Investment Research: <http://www.csfb.com/research> and <http://www.csfb.com/research> and <http://www.csfb.com/research>

Credit Suisse does not provide any tax advice. Any statement herein regarding any US federal tax is not intended or written to be used, and cannot be used, by any taxpayer for the purposes of avoiding any penalties.

Price Target: (12 months) for ZS Pharma, Inc. (ZSPH.OQ)

Method: Our \$51 target price for ZSPH is based on discounted cash flow valuation. We use a 11.5% weighted average cost of capital and forecast discounted cash flows through 2033, with no terminal value thereafter.

Risk: Risks to our \$51 target price for ZSPH are (1) clinical setbacks (2) poor execution and (3) earlier-than-expected generic competition for ZS-9.

Please refer to the firm's disclosure website at <https://rave.credit-suisse.com/disclosures> for the definitions of abbreviations typically used in the target price method and risk sections.

See the Companies Mentioned section for full company names

The subject company (ZSPH.OQ) currently is, or was during the 12-month period preceding the date of distribution of this report, a client of Credit Suisse.

Credit Suisse provided investment banking services to the subject company (ZSPH.OQ) within the past 12 months.

Credit Suisse has managed or co-managed a public offering of securities for the subject company (ZSPH.OQ) within the past 12 months.

Credit Suisse has received investment banking related compensation from the subject company (ZSPH.OQ) within the past 12 months

Credit Suisse expects to receive or intends to seek investment banking related compensation from the subject company (ZSPH.OQ) within the next 3 months.

As of the date of this report, Credit Suisse makes a market in the following subject companies (ZSPH.OQ).

Important Regional Disclosures

Singapore recipients should contact Credit Suisse AG, Singapore Branch for any matters arising from this research report.

The analyst(s) involved in the preparation of this report have not visited the material operations of the subject company (ZSPH.OQ) within the past 12 months

Restrictions on certain Canadian securities are indicated by the following abbreviations: NVS--Non-Voting shares; RVS--Restricted Voting Shares; SVS--Subordinate Voting Shares.

Individuals receiving this report from a Canadian investment dealer that is not affiliated with Credit Suisse should be advised that this report may not contain regulatory disclosures the non-affiliated Canadian investment dealer would be required to make if this were its own report.

For Credit Suisse Securities (Canada), Inc.'s policies and procedures regarding the dissemination of equity research, please visit http://www.csfb.com/legal_terms/canada_research_policy.shtml.

Credit Suisse has acted as lead manager or syndicate member in a public offering of securities for the subject company (ZSPH.OQ) within the past 3 years.

As of the date of this report, Credit Suisse acts as a market maker or liquidity provider in the equities securities that are the subject of this report.

Principal is not guaranteed in the case of equities because equity prices are variable.

Commission is the commission rate or the amount agreed with a customer when setting up an account or at any time after that.

For Credit Suisse disclosure information on other companies mentioned in this report, please visit the website at <https://rave.credit-suisse.com/disclosures> or call +1 (877) 291-2683.

References in this report to Credit Suisse include all of the subsidiaries and affiliates of Credit Suisse operating under its investment banking division. For more information on our structure, please use the following link: <https://www.credit-suisse.com/who-we-are/en>. This report may contain material that is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locally, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Credit Suisse AG or its affiliates ("CS") to any registration or licensing requirement within such jurisdiction. All material presented in this report, unless specifically indicated otherwise, is under copyright to CS. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of CS. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of CS or its affiliates. The information, tools and material presented in this report are provided to you for information purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities or other financial instruments. CS may not have taken any steps to ensure that the securities referred to in this report are suitable for any particular investor. CS will not treat recipients of this report as its customers by virtue of their receiving this report. The investments and services contained or referred to in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about such investments or investment services. Nothing in this report constitutes investment, legal, accounting or tax advice, or a representation that any investment or strategy is suitable or appropriate to your individual circumstances, or otherwise constitutes a personal recommendation to you. CS does not advise on the tax consequences of investments and you are advised to contact an independent tax adviser. Please note in particular that the bases and levels of taxation may change. Information and opinions presented in this report have been obtained or derived from sources believed by CS to be reliable, but CS makes no representation as to their accuracy or completeness. CS accepts no liability for loss arising from the use of the material presented in this report, except that this exclusion of liability does not apply to the extent that such liability arises under specific statutes or regulations applicable to CS. This report is not to be relied upon in substitution for the exercise of independent judgment. CS may have issued, and may in the future issue, other communications that are inconsistent with, and reach different conclusions from, the information presented in this report. Those communications reflect the different assumptions, views and analytical methods of the analysts who prepared them and CS is under no obligation to ensure that such other communications are brought to the attention of any recipient of this report. Some investments referred to in this report will be offered solely by a single entity and in the case of some investments solely by CS, or an associate of CS or CS may be the only market maker in such investments. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a judgment at its original date of publication by CS and are subject to change without notice. The price, value of and income from any of the securities or financial instruments mentioned in this report can fall as well as rise. The value of securities and financial instruments is subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities or financial instruments. Investors in securities such as ADRs, the values of which are influenced by currency volatility, effectively assume this risk. Structured securities are complex instruments, typically involve a high degree of risk and are intended for sale only to sophisticated investors who are capable of understanding and assuming the risks involved. The market value of any structured security may be affected by changes in economic, financial and political factors (including, but not limited to, spot and forward interest and exchange rates), time to maturity, market conditions and volatility, and the credit quality of any issuer or reference issuer. Any investor interested in purchasing a structured product should conduct their own investigation and analysis of the product and consult with their own professional advisers as to the risks involved in making such a purchase. Some investments discussed in this report may have a high level of volatility. High volatility investments may experience sudden and large falls in their value causing losses when that investment is realised. Those losses may equal your original investment. Indeed, in the case of some investments the potential losses may exceed the amount of initial investment and, in such circumstances, you may be required to pay more money to support those losses. Income yields from investments may fluctuate and, in consequence, initial capital paid to make the investment may be used as part of that income yield. Some investments may not be readily realisable and it may be difficult to sell or realise those investments, similarly it may prove difficult for you to obtain reliable information about the value, or risks, to which such an investment is exposed. This report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of CS, CS has not reviewed any such site and takes no responsibility for the content contained therein. Such address or hyperlink (including addresses or hyperlinks to CS's own website material) is provided solely for your convenience and information and the content of any such website does not in any way form part of this document. Accessing such website or following such link through this report and CS's website shall be at your own risk. This report is issued and distributed in Europe (except Switzerland) by Credit Suisse Securities (Europe) Limited, One Cabot Square, London E14 4QJ, England, which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. This report is being distributed in Germany by Credit Suisse Securities (Europe) Limited Niederlassung Frankfurt am Main regulated by the Bundesanstalt fuer Finanzdienstleistungsaufsicht ("BaFin"). This report is being distributed in the United States and Canada by Credit Suisse Securities (USA) LLC; in Switzerland by Credit Suisse AG; in Brazil by Banco de Investimentos Credit Suisse (Brasil) S.A. or its affiliates; in Mexico by Banco Credit Suisse (México), S.A. (transactions related to the securities mentioned in this report will only be effected in compliance with applicable regulation); in Japan by Credit Suisse Securities (Japan) Limited, Financial Instruments Firm, Director-General of Kanto Local Finance Bureau (Kinscho) No. 66, a member of Japan Securities Dealers Association, The Financial Futures Association of Japan, Japan Investment Advisers Association, Type II Financial Instruments Firms Association; elsewhere in Asia/Pacific by whichever of the following is the appropriately authorised entity in the relevant jurisdiction: Credit Suisse (Hong Kong) Limited, Credit Suisse Equities (Australia) Limited, Credit Suisse Securities (Thailand) Limited, regulated by the Office of the Securities and Exchange Commission, Thailand, having registered address at 990 Abdulrahim Place, 27th Floor, Unit 2701, Rama IV Road, Slom, Bangkok, Bangkok 10500, Thailand, Tel. +66 2614 6000, Credit Suisse Securities (Malaysia) Sdn Bhd, Credit Suisse AG, Singapore Branch, Credit Suisse Securities (India) Private Limited (CIN no. U67120MH1996PTC104392) regulated by the Securities and Exchange Board of India (registration Nos. INB230970637, INF230970637, INB010970631), having registered address at 9th Floor, Ceejay House, Dr.A.B. Road, Worli, Mumbai - 18, India, T. +91-22-6777 3777, Credit Suisse Securities (Europe) Limited, Seoul Branch, Credit Suisse AG, Taipei Securities Branch, PT Credit Suisse Securities Indonesia, Credit Suisse Securities (Philippines) Inc., and elsewhere in the world by the relevant authorised affiliate of the above. Research on Taiwanese securities produced by Credit Suisse AG, Taipei Securities Branch has been prepared by a registered Senior Business Person. Research provided to residents of Malaysia is authorised by the Head of Research for Credit Suisse Securities (Malaysia) Sdn Bhd, to whom they should direct any queries on +603 2723 2020. This report has been prepared and issued for distribution in Singapore to institutional investors, accredited investors and expert investors (each as defined under the Financial Advisers Regulations) only, and is also distributed by Credit Suisse AG, Singapore branch to overseas investors (as defined under the Financial Advisers Regulations). By virtue of your status as an institutional investor, accredited investor, expert investor or overseas investor, Credit Suisse AG, Singapore branch is exempted from complying with certain compliance requirements under the Financial Advisers Act, Chapter 110 of Singapore (the "FAA"), the Financial Advisers Regulations and the relevant Notices and Guidelines issued thereunder, in respect of any financial advisory service which Credit Suisse AG, Singapore branch may provide to you. This research may not conform to Canadian disclosure requirements. In jurisdictions where CS is not already registered or licensed to trade in securities, transactions will only be effected in accordance with applicable securities legislation, which will vary from jurisdiction to jurisdiction and may require that the trade be made in accordance with applicable exemptions from registration or licensing requirements. Non-U.S. customers wishing to effect a transaction should contact a CS entity in their local jurisdiction unless governing law permits otherwise. U.S. customers wishing to effect a transaction should do so only by contacting a representative at Credit Suisse Securities (USA) LLC in the U.S. Please note that this research was originally prepared and issued by CS for distribution to their market professional and institutional investor customers. Recipients who are not market professional or institutional investor customers of CS should seek the advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents. This research may relate to investments or services of a person outside of the UK or to other matters which are not authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority or in respect of which the protections of the Prudential Regulation Authority and Financial Conduct Authority for private customers and/or the UK compensation scheme may not be available, and further details as to where this may be the case are available upon request in respect of this report. CS may provide various services to US municipal entities or obligated persons ("municipalities"), including suggesting individual transactions or trades and entering into such transactions. Any services CS provides to municipalities are not viewed as "advice" within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act. CS is providing any such services and related information solely on an arm's length basis and not as an advisor or fiduciary to the municipality. In connection with the provision of the any such services, there is no agreement, direct or indirect, between any municipality (including the officials, management, employees or agents thereof) and CS for CS to provide advice to the municipality. Municipalities should consult with their financial, accounting and legal advisors regarding any such services provided by CS. In addition, CS is not acting for direct or indirect compensation to solicit the municipality on behalf of an unaffiliated broker, dealer, municipal securities dealer, municipal advisor, or investment adviser for the purpose of obtaining or retaining an engagement by the municipality for or in connection with Municipal Financial Products, the issuance of municipal securities, or of an investment adviser to provide investment advisory services to or on behalf of the municipality. If this report is being distributed by a financial institution other than Credit Suisse AG, or its affiliates, that financial institution is solely responsible for distribution. Clients of that institution should contact that institution to effect a transaction in the securities mentioned in this report or require further information. This report does not constitute investment advice by Credit Suisse to the clients of the distributing financial institution, and neither Credit Suisse AG, its affiliates, and their respective officers, directors and employees accept any liability whatsoever for any direct or consequential loss arising from their use of this report or its content. Principal is not guaranteed. Commission is the commission rate or the amount agreed with a customer when setting up an account or at any time after that.

Copyright © 2014 CREDIT SUISSE AG and/or its affiliates. All rights reserved.

Investment principal on bonds can be eroded depending on sale price or market price. In addition, there are bonds on which investment principal can be eroded due to changes in redemption amounts. Care is required when investing in such instruments.

When you purchase non-listed Japanese fixed income securities (Japanese government bonds, Japanese municipal bonds, Japanese government guaranteed bonds, Japanese corporate bonds) from CS as a seller, you will be requested to pay the purchase price only